Despite the high cure rate of Hodgkin lymphoma (HL), decisions regarding therapy for individual patients aimed at optimizing outcome while minimizing acute toxicity and late effects remain challenging. The role of consolidative radiotherapy in early stage disease remains controversial, and clinical prognostic markers including interim and end of treatment PET scans have provided an imperfect approach to risk-based therapy. Incorporation of new and perhaps less toxic agents such as brentuximab vedotin or PD1 inhibitors into earlier lines of therapy is under investigation. Dr. Bartlett will discuss interim PET directed front-line treatment approaches to HL and the utilization of new agents in relapsed HL.
Nancy L. Bartlett
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members